Involvement of 5-HT1AReceptors in Prefrontal Cortex in the Modulation of Dopaminergic Activity: Role in Atypical Antipsychotic Action
Open accessThe DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Abstract
Atypical antipsychotics increase dopamine (DA) release in the medial prefrontal cortex (mPFC), an effect possibly involved in the superior effects of atypical versus classical antipsychotics on cognitive/negative symptoms. We examined the role of 5-HT 1A receptors in the mPFC on the modulation of dopaminergic activity and the mesocortical DA release in vivo. The highly selective 5-HT 1A agonist BAY x 3702 (BAY; 10-40 μg/kg, i.v.) increased the firing rate and burst firing of DA neurons in the ventral tegmental area (VTA) and DA release in the VTA and mPFC. The increase in DA release in both areas was potentiated by nomifensine coperfusion. The selective 5-HT 1A antagonist WAY-100635 reversed the effects of BAY in both areas, and the changes in the VTA were prevented by frontocortical transection. The application of BAY in rat and mouse mPFC by reverse dialysis increased local extracellular DA at a low concentration (3 μ m) and reduced it at a higher concentration (30 μ m). Both effects disappeared in 5-HT 1A knock-out mice. In the presence of bicuculline, BAY reduced DA release at all concentrations. The atypical antipsychotics clozapine, olanzapine, and ziprasidone (but not haloperidol) enhanced DA release in the mPFC of wild-type but not 5-HT 1A knock-out mice after systemic and local (clozapine and olanzapine) administration in the mPFC. Likewise, bicuculline coperfusion prevented the elevation of DA release produced by local clozapine or olanzapine application. These results suggest that the activation of mPFC 5-HT 1A receptors enhances the activity of VTA DA neurons and mesocortical DA release. This mechanism may be involved in the elevation of extracellular DA produced by atypical antipsychotics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Rat Brain in Stereotaxic Coordinates
(1982) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 51,963
The Mouse Brain in Stereotaxic Coordinates
Paxinos, G. (2001) · Cited by 13,440
AChE-stained horizontal sections of the rat brain in stereotaxic coordinates
Paxinos, G., Watson, C. R. R., & Emson, P. C. (1980) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(80)90021-7 · Cited by 4,497
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Pazos, A., & Palacios, J. M. (1985) · Brain Research · doi:10.1016/0006-8993(85)90856-x · Cited by 1,855
Modulation of memory fields by dopamine Dl receptors in prefrontal cortex
Williams, G. V., & Goldman-Rakic, P. S. (1995) · Nature · doi:10.1038/376572a0 · Cited by 1,593
The control of firing pattern in nigral dopamine neurons: burst firing
Grace, A., & Bunney, B. (1984) · The Journal of Neuroscience · doi:10.1523/jneurosci.04-11-02877.1984 · Cited by 1,344
Laruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291
Floresco, S. B., West, A. R., Ash, B., Moore, H., & Grace, A. A. (2003) · Nature Neuroscience · doi:10.1038/nn1103 · Cited by 1,106
Increased baseline occupancy of D 2 receptors by dopamine in schizophrenia
Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., Weiss, R., Cooper, T. B., Mann, J. J., Van Heertum, R. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.8104 · Cited by 1,020 · cited 1×
“Psychotic and cognitive/negative symptoms in schizophrenia seem to be associated with an overactivity of the mesolimbic pathway and a hypofunction of the mesocortical pathway, respectively (Carlsson, 1988; Weinberger et al., 1994; Laruelle et al., 1996; Abi-Dargham et al., 2000).”
BackgroundThe current status of the dopamine hypothesis of schizophrenia
CARLSSON, A. (1988) · Neuropsychopharmacology · doi:10.1016/0893-133x(88)90012-7 · Cited by 958
Carr, D. B., & Sesack, S. R. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-10-03864.2000 · Cited by 880
Seeman, P., & Lee, T. (1975) · Science · doi:10.1126/science.1145194 · Cited by 869 · cited 1×
“Classical neuroleptics used to treat schizophrenia block DA D2 receptors (Seeman and Lee, 1975; Creese et al., 1976), an action that also evokes extrapyramidal motor symptoms and hyperprolactinemia.”
BackgroundElectrophysiological responses of serotoninergic dorsal raphe neurons to 5‐HT1A and 5‐HT1B agonists
Sprouse, J. S., & Aghajanian, G. K. (1987) · Synapse · doi:10.1002/syn.890010103 · Cited by 845
Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence
Arnt, J. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00112-7 · Cited by 715
Pompeiano, M., Palacios, J., & Mengod, G. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-02-00440.1992 · Cited by 698
Increased anxiety of mice lacking the serotonin 1A receptor
Parks, C. L., Robinson, P. S., Sibille, E., Shenk, T., & Toth, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10734 · Cited by 691
Self-citationThe Role of Serotonin in Antipsychotic Drug Action
Meltzer, H. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00046-9 · Cited by 662
Araneda, R., & Andrade, R. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90128-b · Cited by 625
A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635
Forster, E. A., Cliffe, I. A., Bill, D. J., Dover, G. M., Jones, D., Reilly, Y., & Fletcher, A. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00234-c · Cited by 612
Sesack, S. R., Hawrylak, V. A., Matus, C., Guido, M. A., & Levey, A. I. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-07-02697.1998 · Cited by 582
Schultz, W. (2004) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2004.03.017 · Cited by 517
Riad, M., Garcia, S., Watkins, K. C., Jodoin, N., Doucet, �., Langlois, X., El Mestikawy, S., Hamon, M., & Descarries, L. (2000) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(20000207)417:2<181::aid-cne4>3.0.co;2-a · Cited by 513
Peyron, C., Petit, J.-M., Rampon, C., Jouvet, M., & Luppi, P.-H. (1997) · Neuroscience · doi:10.1016/s0306-4522(97)00268-6 · Cited by 509
Celada, P., Puig, M. V., Casanovas, J. M., Guillazo, G., & Artigas, F. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-24-09917.2001 · Cited by 497
Self-citationIchikawa, J., Ishii, H., Bonaccorso, S., Fowler, W. L., O'Laughlin, I. A., & Meltzer, H. Y. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00154.x · Cited by 494
Santana, N. (2004) · Cerebral Cortex · doi:10.1093/cercor/bhh070 · Cited by 486
Chemical neuromodulation of frontal-executive functions in humans and other animals
Robbins, T. W. (2000) · Experimental Brain Research · doi:10.1007/s002210000407 · Cited by 396
Murase, S., Grenhoff, J., Chouvet, G., Gonon, F. G., & Svensson, T. H. (1993) · Neuroscience Letters · doi:10.1016/0304-3940(93)90641-w · Cited by 387 · cited 1×
“Likewise, chemical and electrical stimulation of the mPFC enhanced DA neuron activity and DA release in the VTA (Murase et al., 1993; Bortolozzi et al., 2005).”
BackgroundHabenular and other midbrain raphe afferents demonstrated by a modified retrograde tracing technique
Aghajanian, G. K., & Wang, R. Y. (1977) · Brain Research · doi:10.1016/0006-8993(77)90291-8 · Cited by 380
Immunocytochemical localization of serotonin1A receptors in the rat central nervous system
Kia, H. K., Miquel, M.-C., Brisorgueil, M.-J., Daval, G., Riad, M., Mestikawy, S. E., Hamon, M., & Verg�, D. (1996) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19960205)365:2<289::aid-cne7>3.0.co;2-1 · Cited by 378
Amargos-Bosch, M. (2004) · Cerebral Cortex · doi:10.1093/cercor/bhg128 · Cited by 370
SESACK, S. R., CARR, D. B., OMELCHENKO, N., & PINTO, A. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.066 · Cited by 367
GABA-containing neurons in the rat ventral tegmental area project to the prefrontal cortex
Carr, D. B., & Sesack, S. R. (2000) · Synapse · doi:10.1002/1098-2396(200011)38:2<114::aid-syn2>3.0.co;2-r · Cited by 352
Kuroki, T., Meltzer, H. Y., & Ichikawa, J. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38019-x · Cited by 351
Martı́n-Ruiz, R., Puig, M. V., Celada, P., Shapiro, D. A., Roth, B. L., Mengod, G., & Artigas, F. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-24-09856.2001 · Cited by 339
Self-citationSharp, T., Bramwell, S. R., & Grahame‐Smith, D. G. (1989) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1989.tb11815.x · Cited by 321
Sprouse, J. S., & Aghajanian, G. K. (1986) · European Journal of Pharmacology · doi:10.1016/0014-2999(86)90782-x · Cited by 306
Cellular localization of the 5-HT receptor in primate brain neurons and glial cells
AZMITIA, E., GANNON, P., KHECK, N., & WHITAKERAZINITIA, P. (1996) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)80057-1 · Cited by 305
Hajós, M., Richards, C. D., Székely, A. D., & Sharp, T. (1998) · Neuroscience · doi:10.1016/s0306-4522(98)00157-2 · Cited by 300
Improving the Treatment of Schizophrenia: Focus on Serotonin (5-HT)1A Receptors
Millan, M. J. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38982-7 · Cited by 287
Gariano, R. F., & Groves, P. M. (1988) · Brain Research · doi:10.1016/0006-8993(88)90606-3 · Cited by 286
Laterodorsal tegmental projections to identified cell populations in the rat ventral tegmental area
Omelchenko, N., & Sesack, S. R. (2005) · The Journal of Comparative Neurology · doi:10.1002/cne.20417 · Cited by 252
Partial agonists, full agonists, antagonists: dilemmas of definition
Hoyer, D., & Boddeke, H. W. G. M. (1993) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(93)90129-8 · Cited by 237
Role of 5-HT2C receptors in the control of central dopamine function
Di Matteo, V., De Blasi, A., Di Giulio, C., & Esposito, E. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01688-6 · Cited by 234
Puig, M. V. (2004) · Cerebral Cortex · doi:10.1093/cercor/bhh104 · Cited by 231
Chergui, K., Suaud-Chagny, M. F., & Gonon, F. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90465-0 · Cited by 229
The activation of 5‐HT2A receptors in prefrontal cortex enhances dopaminergic activity
Bortolozzi, A., Díaz‐Mataix, L., Scorza, M. C., Celada, P., & Artigas, F. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03485.x · Cited by 224
Self-citationPorras, G. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00333-5 · Cited by 222
Tzschentke, T. M., & Schmidt, W. J. (2000) · Critical Reviews™ in Neurobiology · doi:10.1615/critrevneurobiol.v14.i2.20 · Cited by 218
Prisco, S., Pagannone, S., & Esposito, E. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22843-9 · Cited by 214
Hajós, M., Hajós‐Korcsok, É., & Sharp, T. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702510 · Cited by 210
Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation
Rollema, H., Lu, Y., Schmidt, A. W., & Zorn, S. H. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)81951-6 · Cited by 203
(1994) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.6.4.419 · Cited by 196
Rollema, H., Lu, Y., Schmidt, A. W., Sprouse, J. S., & Zorn, S. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00850-7 · Cited by 195
Influence of the hippocampus on interneurons of the rat prefrontal cortex
Tierney, P. L., Dégenètais, E., Thierry, A., Glowinski, J., & Gioanni, Y. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03501.x · Cited by 192
The mesocortico-prefrontal dopaminergic neurons
Glowinski, J., Tassin, J. P., & Thierry, A. M. (1984) · Trends in Neurosciences · doi:10.1016/s0166-2236(84)80145-9 · Cited by 192
Adell, A., & Artigas, F. (2004) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2004.05.001 · Cited by 189
Self-citationTong, Z.-Y., Overton, P. G., & Clark, D. (1996) · Synapse · doi:10.1002/(sici)1098-2396(199603)22:3<195::aid-syn1>3.0.co;2-7 · Cited by 189
Arborelius, L., Chergui, K., Murase, S., Nomikos, G. G., Backlund H��k, B., Chouvet, G., Hacksell, U., & Svensson, T. H. (1993) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/bf00165384 · Cited by 165
Celada, P., Paladini, C. A., & Tepper, J. M. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00356-x · Cited by 152
Self-citationFerre, S., Cortes, R., & Artigas, F. (1994) · The Journal of Neuroscience · doi:10.1523/jneurosci.14-08-04839.1994 · Cited by 150
Self-citationSakaue, M., Somboonthum, P., Nishihara, B., Koyama, Y., Hashimoto, H., Baba, A., & Matsuda, T. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703139 · Cited by 143
Ceci, A., Baschirotto, A., & Borsini, F. (1994) · Neuropharmacology · doi:10.1016/0028-3908(94)90177-5 · Cited by 137
Adell, A., Carceller, A., & Artigas, F. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb13390.x · Cited by 136
Self-citationPostsynaptic 5-HT1A receptors control 5-HT release in the rat medial prefrontal cortex
Casanovas, J. M., Hervás, I., & Artigas, F. (1999) · NeuroReport · doi:10.1097/00001756-199905140-00010 · Cited by 118
Self-citationAshby, C. R., Edwards, E., & Wang, R. Y. (1994) · Synapse · doi:10.1002/syn.890170306 · Cited by 116
Gessa, G. L., Devoto, P., Diana, M., Flore, G., Melis, M., & Pistis, M. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00087-7 · Cited by 115
DeFelipe, J., Arellano, J. I., Gómez, A., Azmitia, E. C., & Muñoz, A. (2001) · Journal of Comparative Neurology · doi:10.1002/cne.1132 · Cited by 107
Czyrak, A., Czepiel, K., Maćkowiak, M., Chocyk, A., & Wędzony, K. (2003) · Brain Research · doi:10.1016/s0006-8993(03)03352-3 · Cited by 107
(R)‐8‐OH‐DPAT preferentially increases dopamine release in rat medial prefrontal cortex
Arborelius, L., Nomikos, G. G., Hacksell, U., & Svensson, T. H. (1993) · Acta Physiologica Scandinavica · doi:10.1111/j.1748-1716.1993.tb09584.x · Cited by 102
Lejeune, F., & Millan, M. J. (1998) · Synapse · doi:10.1002/(sici)1098-2396(199810)30:2<172::aid-syn7>3.0.co;2-9 · Cited by 99
Beck, S. G., Choi, K. C., & List, T. J. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10347-9 · Cited by 98
Atypical antipsychotic drug actions: unitary or multiple mechanisms for ‘atypicality’?
Roth, B. L., Sheffler, D. J., & Potkin, S. G. (2003) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(03)00021-5 · Cited by 94
Ichikawa, J., Kuroki, T., Kitchen, M. T., & Meltzer, H. Y. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00624-9 · Cited by 78
Effects of stimulation of the frontal cortex on identified output VMT cells in the rat
Thierry, A. M., Deniau, J., & Féger, J. (1979) · Neuroscience Letters · doi:10.1016/0304-3940(79)96097-x · Cited by 69
Bortolozzi, A., Amargós‐Bosch, M., Adell, A., Díaz‐Mataix, L., Serrats, J., Pons, S., & Artigas, F. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02829.x · Cited by 61
Self-citationLucas, G., Matteo, V. D., Deurwaerdère, P. D., Porras, G., Martín‐Ruiz, R., Artigas, F., Esposito, E., & Spampinato, U. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2000.01453.x · Cited by 60
Self-citationThierry, A. M., Chevalier, G., Ferron, A., & Glowinski, J. (1983) · Experimental Brain Research · doi:10.1007/bf00239191 · Cited by 58
DOI, a 5-HT2A/2C receptor agonist, attenuates clozapine-induced cortical dopamine release
Ichikawa, J., Dai, J., & Meltzer, H. Y. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02596-3 · Cited by 56
Kuroki, T., Ichikawa, J., Dai, J., & Meltzer, H. Y. (1996) · Brain Research · doi:10.1016/s0006-8993(96)01111-0 · Cited by 56
Borsini, F., Ceci, A., Bietti, G., & Donetti, A. (1995) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00168558 · Cited by 52
Díaz-Mataix, L., Artigas, F., & Celada, P. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.10.003 · Cited by 49
Self-citationOccupancy of 5-HT1A receptors by clozapine in the primate brain: a PET study
Chou, Y.-H., Halldin, C., & Farde, L. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1256-2 · Cited by 46
Tong, Z.-Y., Overton, P. G., Martínez‐Cué, C., & Clark, D. (1998) · Experimental Brain Research · doi:10.1007/s002210050303 · Cited by 43
Fà, M., Mereu, G., Ghiglieri, V., Meloni, A., Salis, P., & Gessa, G. L. (2003) · Synapse · doi:10.1002/syn.10177 · Cited by 39
Casanovas, J. M., Berton, O., Celada, P., & Artigas, F. (2000) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s002100000291 · Cited by 38
Self-citation
Cited by
Nichols, D. E., & Nichols, C. D. (2008) · Chemical Reviews · doi:10.1021/cr078224o · Cited by 895
Pfaus, J. G. (2009) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2009.01309.x · Cited by 678
Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission
Alex, K. D., & Pehek, E. A. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.08.004 · Cited by 658
Sanchez, C., Asin, K. E., & Artigas, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.001 · Cited by 547
Self-citationSerotonin modulation of cortical neurons and networks
Celada, P., Puig, M. V., & Artigas, F. (2013) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2013.00025 · Cited by 462
“Despite its low in vitro affinity for 5-HT1A receptors, the reversal by clozapine of PCP effects depends on the in vivo stimulation of such receptors (Kargieman et al., 2012), as previously observed for the antipsychotic-evoked release of dopamine in mPFC (Diaz-Mataix et al., 2005).”
BackgroundSelf-citation
Metadata
- Authors
- Díaz-Mataix, L., Scorza, M. C., Bortolozzi, A., Toth, M., Celada, P., & Artigas, F.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2005-11-23
- Volume
- 25
- Issue
- 47
- Pages
- 10831-10843
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2037409999
- Cited by
- 285
- References
- 87
- FWCI
- 8.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.